A pivotal study published on April 23, 2024, in the Journal of Clinical Oncology explored the efficacy of Datopotamab Deruxtecan (Dato-DXd) in advanced HR+/HER2– and triple-negative breast cancer (TNBC). Led by Dr. Aditya Bardia, the study reported an objective response rate of 26.8% in HR+/HER2– breast cancer and 31.8% in TNBC, with a median progression-free survival of 8.3 months and 4.4 months, respectively.
The treatment showed promising clinical activity and a manageable safety profile, with stomatitis being the most common adverse event. These findings provide valuable insights into the potential of Dato-DXd, supporting its further evaluation in Phase III trials.
A big thank you to the experts behind this important research!
For more details: https://lnkd.in/emSaqcmv
